The neuroendocrine carcinoma market is experiencing steady growth driven by rising disease prevalence and improved diagnostic capabilities. Advancements in targeted therapies and immunotherapies are expanding treatment options and boosting market demand. Additionally, ongoing clinical research of therapies such as obrixtamig (BI 764532) (Boehringer Ingelheim and Oxford BioTherapeutics), gocatamig (MK-6070) (Merck and Daiichi Sankyo), ZL-1310 (Zai Lab and MediLink Therapeutics), peluntamig (PT217) (Phanes Therapeutics), and others and investment from pharmaceutical developers are expected to further accelerate market expansion in the coming years.

LAS VEGAS, March 9, 2026 /PRNewswire/ -- Recently published Neuroendocrine Carcinoma Market Insights report includes a comprehensive understanding of current treatment practices, neuroendocrine carcinoma emerging drugs, market share of individual therapies, and current and forecasted market size from 2022 to 2036, segmented into leading markets [the United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan]. 

Neuroendocrine Carcinoma Market Summary

• The total neuroendocrine carcinoma treatment market size is expected to grow positively by 2036 in the leading markets.
• The United States accounted for the largest neuroendocrine carcinoma treatment market size in 2025, compared to other major markets, including the EU4 countries (Germany, France, Italy, and Spain), the United Kingdom, and Japan.
• In the US, NECs represent only 10%–20% of all NENs, which are highly proliferative tumors characterized by rapid disease progression.
• Leading neuroendocrine carcinoma companies, such as Boehringer Ingelheim, Oxford BioTherapeutics, Merck, Daiichi Sankyo, Zai Lab, MediLink Therapeutics, Phanes Therapeutics, Legend Biotech, Novartis, Abdera Therapeutics, Amgen, and others, are developing new neuroendocrine carcinoma treatment drugs that can be available in the neuroendocrine carcinoma market in the coming years. 
• The promising neuroendocrine carcinoma therapies in clinical trials include Obrixtamig (BI 764532), gocatamig (MK-6070), ZL-1310, peluntamig (PT217), LB2102, ABD147, IMDELLTRA (tarlatamab), and others.

Discover forecast CAGR for neuroendocrine carcinoma treatment market @ https://www.delveinsight.com/sample-request/neuroendocrine-carcinoma-market?utm_source=cision&utm_medium=pressrelease&utm_campaign=spr

Key Factors Driving the Growth of the Neuroendocrine Carcinoma Market 

• Rising NEC Incidence: The global increase in diagnosed cases of neuroendocrine tumors (including carcinomas) is a major market growth driver. This uptick is driven by better detection and reporting, alongside an aging population more susceptible to cancer.
• Biomarker-Driven Approaches in Modern Oncology: Advances in molecular profiling have identified recurrent alterations such as TP53 and RB1 loss, as well as potential DNA repair pathway vulnerabilities. This growing biological understanding provides a scientific rationale for exploring targeted therapies and biomarker-driven approaches.
• Role of Platinum-Based Chemotherapy in Advanced NEC: Platinum-based chemotherapy (cisplatin or carboplatin plus etoposide) remains an established global standard of care, producing relatively high objective response rates in newly diagnosed advanced NEC.
• Next-Generation Approaches in Targeted Cancer Therapy: Therapeutic strategies targeting DLL3, antibody-drug conjugates, bispecific T-cell engagers, and other tumor-specific markers may offer new mechanisms beyond cytotoxic chemotherapy.
• Actionable Genomic Subsets in Oncology: Broader implementation of genomic testing may identify actionable subsets, including MSI-high tumors, high tumor mutational burden, NTRK fusions, or DNA repair deficiencies. Even if rare, these subsets offer potential for durable responses with targeted therapies.
• Launch of Emerging Therapies: The dynamics of the NECs market are expected to change in the coming years due to the launch of emerging therapies such as obrixtamig (BI 764532) (Boehringer Ingelheim and Oxford BioTherapeutics), gocatamig (MK-6070) (Merck and Daiichi Sankyo), ZL-1310 (Zai Lab and MediLink Therapeutics), peluntamig (PT217) (Phanes Therapeutics), LB2102 (Legend Biotech and Novartis), ABD147 (Abdera Therapeutics), IMDELLTRA (tarlatamab) (Amgen), and others.

Aparna Thakur, Assistant Project Manager, Forecasting and Analytics at DelveInsight, said that novel therapeutic strategies beyond platinum chemotherapy are urgently needed for NEC and are being actively investigated in clinical trials, including immunotherapy combinations and molecularly targeted approaches that could eventually redefine standard care.

Neuroendocrine Carcinoma Market Analysis

• Unlike well-differentiated neuroendocrine tumors (NETs), NEC behaves biologically similar to small cell carcinoma and is typically diagnosed at an advanced or metastatic stage. Despite growing disease recognition, therapeutic innovation remains limited, and outcomes remain poor.
• First-line therapy typically consists of platinum-based chemotherapy (cisplatin or carboplatin) combined with etoposide. 
• While initial response rates can be relatively high, responses are often short-lived, with rapid relapse, and median Overall Survival (mOS) generally ranges between 8–15 months, depending on primary site and stage.
• In localized cases, multimodal treatment, including surgery, chemotherapy, and sometimes radiotherapy, may be considered, but recurrence rates remain high even after aggressive management.
• Second-line treatment options are not standardized and generally provide modest benefit. Regimens such as FOLFIRI/FOLFOX, temozolomide-based combinations, or re-challenge with platinum in select patients are used in practice, but durable disease control is uncommon.
• Delta-like ligand 3 (DLL3) has evolved from an obscure Notch ligand into a key oncology biomarker, impacting Small Cell Lung Cancer (SCLC), NETs, NEC, including Neuroendocrine Prostate Cancer (NEPC) and Extra-pulmonary NEC (EP-NEC), and Large cell Neuroendocrine Lung Carcinoma (LCNEC). 
• Several companies have advanced gene therapies into clinical trials, including Boehringer Ingelheim and Oxford BioTherapeutics (obrixtamig [BI 764532]), Merck and Daiichi Sankyo (gocatamig [MK-6070]), Zai Lab and MediLink Therapeutics (ZL-1310), Phanes Therapeutics (peluntamig [PT217]), Legend Biotech and Novartis (LB2102), Abdera Therapeutics, Amgen (IMDELLTRA), and others.

Neuroendocrine Carcinoma Competitive Landscape

Some of the NEC drugs under development include obrixtamig (BI 764532) (Boehringer Ingelheim and Oxford BioTherapeutics), gocatamig (MK-6070) (Merck and Daiichi Sankyo), ZL-1310 (Zai Lab and MediLink Therapeutics), peluntamig (PT217) (Phanes Therapeutics), LB2102 (Legend Biotech and Novartis), ABD147 (Abdera Therapeutics), IMDELLTRA (tarlatamab) (Amgen), and others.

Boehringer Ingelheim and Oxford BioTherapeutics' BI 764532 is an investigational IgG-like DLL3/CD3 T-cell engager under development by Boehringer Ingelheim for the potential treatment of patients with LCNEC. The molecule (also known as OBT620) originated from a 2013 collaboration that combined Oxford BioTherapeutics' OGAP platform—used to identify DLL3 antigens, with the oncology and biotherapeutic development capabilities of Boehringer Ingelheim. Obrixtamig (BI 764532) is currently being studied in this patient group in the Phase II DAREON-5 clinical trial (NCT05882058).

Merck and Daiichi Sankyo's MK-6070 is a tri-specific, DLL3-targeted T-cell engager that is being assessed in an ongoing Phase I/II clinical study involving patients with NEPC. In August 2024, Daiichi Sankyo and Merck broadened their partnership in antibody–drug conjugates to include MK-6070, agreeing to co-develop and co-commercialize the agent globally, with Merck maintaining rights in Japan as well as manufacturing responsibilities.

Zai Lab and MediLink Therapeutics' ZL-1310 is composed of a humanized anti-DLL3 monoclonal antibody linked via a cleavable connector to a novel camptothecin-based topoisomerase I inhibitor. This agent was engineered using the TMALIN ADC platform, designed to exploit the tumor microenvironment and address limitations seen in earlier-generation ADCs. Zai Lab initiated a Phase I/II trial of ZL-1310 for solid tumors, including NECs, in May 2025.

The anticipated launch of these emerging therapies are poised to transform the neuroendocrine carcinoma market landscape in the coming years. As these cutting-edge therapies continue to mature and gain regulatory approval, they are expected to reshape the neuroendocrine carcinoma market landscape, offering new standards of care and unlocking opportunities for medical innovation and economic growth.

Discover more about emerging drugs in NEC treatment pipeline @ Neuroendocrine Carcinoma Drugs 

Recent Developments in the Neuroendocrine Carcinoma Market

• In October 2025, Boehringer Ingelheim presented the data from the Phase II DAREON-5 trial of obrixtamig in patients with relapsed/refractory DLL3 -high expressing EP-NEC at the European Society for Medical Oncology (ESMO) 2025. 
• In June 2025, Legend Biotech presented the Phase I dose-escalating study of LB2102 at the American Society of Clinical Oncology (ASCO) 2025, which demonstrated no Dose Limiting Toxicities (DLTs), and a preliminary efficacy signal was observed up to four dose levels in patients with relapsed or refractory SCLC and LCNEC.

What is Neuroendocrine Carcinoma?

Neuroendocrine carcinoma is an aggressive type of cancer that arises from neuroendocrine cells, specialized cells found throughout the body that have characteristics of both nerve cells and hormone-producing endocrine cells. These tumors can develop in many organs, most commonly in the lungs, gastrointestinal tract, and pancreas. Unlike slower-growing neuroendocrine tumors, neuroendocrine carcinomas tend to grow and spread rapidly, often requiring prompt diagnosis and intensive treatment such as chemotherapy, radiation, or targeted therapies. Because their symptoms can be vague or mimic other conditions, early detection can be challenging, making awareness and timely medical evaluation especially important.

Neuroendocrine Carcinoma Epidemiology Segmentation

The neuroendocrine carcinoma epidemiology section provides insights into the historical and current neuroendocrine carcinoma patient pool and forecasted trends for the leading markets. In NECs, the majority occur in the lung (31.1%), followed in decreasing frequency by stomach, pancreas, rectum, and esophagus. The remaining organs in NECs included the uterus, oral cavity, thymus, mediastinum, and ovary.

The neuroendocrine carcinoma treatment market report proffers epidemiological analysis for the study period 2022–2036 in the leading markets, segmented into:

• Total Incident Cases of NECs
• Grade-specific Incident Cases of NECs
• Stage-specific Incident Cases of NECs
• Site-specific Incident Cases of NECs
• Subtype-specific Incident Cases of NECs
• Total Incident Cases of NECs with DLL3 Expression
• Total Treated Cases of NECs

Scope of the Neuroendocrine Carcinoma Market Report

• Therapeutic Assessment: Neuroendocrine Carcinoma current marketed and emerging therapies
• Neuroendocrine Carcinoma Market Dynamics: Key Market Forecast Assumptions of Emerging Neuroendocrine Carcinoma Drugs and Market Outlook
• Competitive Intelligence Analysis: SWOT analysis and Market entry strategies
• Unmet Needs, KOL's views, Analyst's views, Neuroendocrine Carcinoma Market Access and Reimbursement

Download the report to understand unmet needs in neuroendocrine carcinoma treatment @ Neuroendocrine Carcinoma Market Analysis

Table of Contents

Related Reports

Delta-like Ligand 3 Targeted Therapies Market

Delta-like Ligand 3 Targeted Therapies Market Size, Target Population, Competitive Landscape & Market Forecast – 2034 report delivers an in-depth understanding of the market trends, market drivers, market barriers, and key DLL-3 therapies companies including Phanes Therapeutics, Merck, Daiichi Sankyo, Legend Biotech, Novartis, Abdera Therapeutics, Boehringer Ingelheim, Chugai Pharmaceutical, Roche, Molecular Partners, Oranomed, Zai Lab, Allogene Therapeutics, Amgen, and others.

Neuroendocrine Tumors Market

Neuroendocrine Tumors Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key neuroendocrine tumors companies including Novartis, Merck, Pfizer, ITM Solucin GMBH, Camurus, Bristol Myers Squibb, Rayzebio, Exelixis, Ipsen, Takeda, Radiomedix, Orano Med, Perspective Therapeutics, Elicera Therapeutics, Chimerix, Enterome, Teclison, and others.

Gastroenteropancreatic Neuroendocrine Tumors Market

Gastroenteropancreatic Neuroendocrine Tumors Market Insights, Epidemiology, and Market Forecast – 2034 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key GEP-NET companies including Novartis, Ipsen Biopharmaceuticals, Pfizer, ITM Isotopen Technologien Muenchen, Camurus AB, Hutchison Medipharma Limited, Bristol-Myers Squibb, Eisai Limite, Experior S.L., Tarveda Therapeutics, Roche Pharma A, Exelixis, Merck Sharp & Dohme Corp, Recordati Inc, Eli Lilly and Company, Genentech, Inc., Aveo Oncology Pharmaceuticals, Radiomedix, Orano Med, PharmaMar, Bayer, Trio Medicines, among others.

Neuroendocrine Prostate Cancer Market

Neuroendocrine Prostate Cancer Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key neuroendocrine prostate cancer companies, including Pfizer, Novartis, Bristol-Myers Squibb, Exelixis, Ipsen, Takeda, among others.

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

Contact Us

Shruti Thakur

info@delveinsight.com

+14699457679

www.delveinsight.com

Logo: https://mma.prnewswire.com/media/1082265/3528414/DelveInsight_Logo.jpg

View original content:https://www.prnewswire.co.uk/news-releases/neuroendocrine-carcinoma-market-poised-for-significant-growth-during-the-forecast-period-20262036-driven-by-rising-incidence-and-advancements-in-targeted-therapies--delveinsight-302707874.html

Zalando hat 2025 kräftig zugelegt und seine eigenen Ziele am oberen Ende der Spannen erreicht. Der Umsatz des im DAX notierten Online-Modehändlers stieg um 16,8 Prozent auf 12,35 Milliarden Euro und lag damit leicht über den Markterwartungen. Das Bruttowarenvolumen (GMV) kletterte um 14,7 Prozent auf 17,56 Milliarden Euro. Rückenwind bekam das Geschäft vor allem durch die Übernahme des Konkurrenten About You sowie den verstärkten Einsatz Künstlicher Intelligenz in Vertrieb und Plattformsteuerung.

Operativ verbesserte sich Zalando ebenfalls: Das bereinigte Ergebnis vor Zinsen und Steuern (EBIT) erhöhte sich auf 591 Millionen Euro nach 511 Millionen Euro im Vorjahr, die Marge blieb mit 4,8 Prozent stabil und leicht über den Analystenprognosen. Unter dem Strich sank der Gewinn jedoch auf 213 Millionen Euro von zuvor 251 Millionen Euro und verfehlte damit die Erwartungen. Für das laufende Jahr stellt das Management ein weiteres Wachstum von 12 bis 17 Prozent bei GMV und Umsatz in Aussicht; das bereinigte EBIT soll auf 660 bis 740 Millionen Euro steigen. Die mittelfristigen Ziele bis 2028 – jährliche Zuwächse von 8 bis 13 Prozent bei Umsatz und GMV sowie eine EBIT-Marge von 6 bis 8 Prozent – wurden bestätigt, die angepeilten jährlichen Synergien aus der About-You-Übernahme von 100 Millionen Euro sollen bereits 2028 und damit ein Jahr früher erreicht sein.

An der Börse sorgte vor allem die Kapitalmarktpolitik für Auftrieb. Der Konzern kündigte ein Aktienrückkaufprogramm von bis zu 300 Millionen Euro an, das bis Ende Juli laufen soll. Die Aktie legte im Tagesverlauf zweistellig zu und notierte zeitweise rund elf Prozent höher bei 22,35 Euro. Damit reagierte der Markt positiv auf die Kombination aus besser als erwarteten operativen Kennzahlen, bestätigtem Wachstumskurs und der Ankündigung, überschüssiges Kapital an die Anteilseigner zurückzuführen – obwohl die Zalando-Papiere seit Jahresbeginn deutlich im Minus liegen und in den vergangenen zwölf Monaten rund ein Drittel an Wert verloren haben. Analysten hoben neben dem Rückkauf insbesondere die Rolle von KI und das Konzept des sogenannten Agentic Commerce als nächste Entwicklungsstufe des Onlinehandels hervor.

Überschattet werden die guten Zahlen von strukturellen Einschnitten im Logistiknetz. Im Zuge der Integration von About You will Zalando vier Logistikzentren in Europa schließen, darunter den Standort Erfurt mit rund 2.700 Beschäftigten. Co-Chef David Schröter sprach von einer der schwersten, zugleich aber notwendigen Entscheidungen, um die Kapazitäten an den künftigen Wachstumsbedarf anzupassen. Das Unternehmen verhandelt nach eigenen Angaben mit dem Betriebsrat über einen Sozialplan, bietet Versetzungen an andere Standorte an und arbeitet mit der örtlichen Arbeitsagentur zusammen. Weitere Maßnahmen über die bereits angekündigten Schließungen hinaus soll es dem Management zufolge nicht geben; aus der Thüringer Landespolitik kommt dennoch Kritik an der Entscheidung.